Rapid diagnostic HCV antibody assays

Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA. .
Antiviral therapy (Impact Factor: 3.02). 01/2012; 17(7 Pt B):1409-13. DOI: 10.3851/IMP2470
Source: PubMed


Approximately 4.1 million Americans have been infected with HCV and 45-85% of chronically infected persons are unaware of their status. Rapid anti-HCV assays can assist and expedite the identification of those unaware of their infection. Performance characteristics of pre-market rapid anti-HCV assays (Chembio, MedMira and OraSure) have been evaluated. Their sensitivity (78.9-99.3%) and specificity (80-100%) varied. Future investigations could include evaluation of rapid anti-HCV tests in persons who are coinfected with HCV and HIV, and development of rapid HCV-antigen tests and nucleic acid tests.

Download full-text


Available from: Amy Jewett
  • Source
    • "Among immuno-competent population reliability of ICT is 95%; while in immunocompromised , it drops to 77.5 % [14] [16] Performance characteristics of pre-market rapid anti-HCV varied in their sensitivity is (78.9-99.3%) and specificity (80- 100%) [14] [15] [16]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pakistan is among the countries with high prevalence rates of Hepatitis B and C virus infections. Proper diagnosis of the disease is very crucial in combating with the high prevalence rates in a country. In Pakistan, numbers of diagnostic tests like Immuno-chromatography technique (ICT), enzyme linked immuno-sorbent assay (ELISA) and polymerase chain reaction (PCR) are in use to demonstrate the presence of hepatitis in the subjects. In the present study, we used ICT, ELISA and PCR techniques and compared the sensitivity and specificity of these techniques in order to evaluate best suited method for local situations. Sensitivity analysis of these tests has shown that ICT has a low detection rate of positive cases in comparison with the ELISA and PCR based nucleic acid detection techniques. We suggest that ELISA and PCR should be used instead of ICT for screening purposes in hospitals, blood banks and diagnostic laboratories.
    Full-text · Article · Mar 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent approvals of direct-acting, orally delivered pharmaceuticals for the treatment of patients with infection by HCV and of a point-of-care assay for community screening of HCV infection have generated impetus to widen the identification of HCV-infected individuals. Diagnosis of HCV infection is, however, still based on the detection of anti-HCV immunoglobulin G. As treatment is intended for individuals with current infection, testing for evidence of infection would need to centre on the detection of HCV viraemia. Minimizing the complexity and costs associated with HCV nucleic acid testing and speeding the development and validation of HCV antigen assays expedite the identification of HCV-viraemic individuals. Establishing means to diagnose recent HCV infection and to engage in surveillance of drug-resistant HCV are also apposite. Successful implementation of these various measures brightens prospects for the eventual elimination of HCV.
    Full-text · Article · Jan 2012 · Antiviral therapy
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Point-of-care tests provide a plausible diagnostic strategy for hepatitis C infection in economically impoverished areas. However, their utility depends upon the overall performance of individual tests. A literature search was conducted using the metasearch engine Mettā, a query interface for retrieving articles from five leading medical databases. Studies were included if they employed point-of-care tests to detect antibodies of hepatitis C virus and compared the results with reference tests. Two reviewers performed a quality assessment of the studies and extracted data for estimating test accuracy. Thirty studies that had evaluated 30 tests fulfilled the inclusion criteria. The overall pooled sensitivity, specificity, positive likelihood-ratio, negative likelihood-ratio and diagnostic odds ratio for all tests were 97.4% (95% CI: 95.9-98.4), 99.5% (99.2-99.7), 80.17 (55.35-116.14), 0.03 (0.02-0.04), and 3032.85 (1595.86-5763.78), respectively. This suggested a high pooled accuracy for all studies. We found substantial heterogeneity between studies, but none of the subgroups investigated could account for the heterogeneity. Genotype diversity of HCV had no or minimal influence on test performance. Of the seven tests evaluated in the meta-regression model, OraQuick had the highest test sensitivity and specificity and showed better performance than a third generation enzyme immunoassay in seroconversion panels. The next highest test sensitivities and specificities were from TriDot and SDBioline, followed by Genedia and Chembio. The Spot and Multiplo tests produced poor test sensitivities but high test specificities. Nine of the remaining 23 tests produced poor test sensitivities and specificities and/or showed poor performances in seroconversion panels, while 14 tests had high test performances with diagnostic odds ratios ranging from 590.70 to 28822.20. Performances varied widely among individual point-of-care tests for diagnosis of hepatitis C virus infection. Physicians should consider this while using specific tests in clinical practice.
    Full-text · Article · Mar 2015 · PLoS ONE
Show more